ストックスクリーナーアプリを入手
15.88
6.20%
-1.05
プレマーケット:
15.91
0.03
+0.19%
前日終値:
$16.93
開ける：
$16.75
24時間の取引高:
1.96M
Relative Volume:
1.00
時価総額：
$1.84B
収益：
$674.41M
当期純損益:
$-173.05M
株価収益率:
-10.35
EPS:
-1.5343
ネットキャッシュフロー:
$-48.07M
1週間 パフォーマンス:
+31.02%
1か月 パフォーマンス:
+50.52%
6か月 パフォーマンス:
+36.78%
1年 パフォーマンス:
-10.59%
1日の値動き範囲:
$15.79
$16.76
1週間の範囲:
$11.61
$17.22
52週間の値動き範囲:
$9.82
$20.06
Novocure Ltd Stock (NVCR) Company Profile
Compare NVCR vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
15.88 | 1.84B | 674.41M | -173.05M | -48.07M | -1.5343 |
ABT
Abbott Laboratories
|
87.17 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-12-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
Why NovoCure (NVCR) Is Up 33.2% After FDA Clears Optune Pax And Guidance Ticks Higher - Sahm
Wells Fargo Maintains Novocure(NVCR.US) With Hold Rating, Raises Target Price to $17 - Moomoo
NovoCure’s Optune Pax Win And TRIDENT Data Shape Growth Outlook - Sahm
NovoCure Limited Surges As Guidance Hike Fuels NVCR Rally - timothysykes.com
Here's What Analysts Are Forecasting For NovoCure Limited (NASDAQ:NVCR) After Its First-Quarter Results - Moomoo
NovoCure Limited (NASDAQ:NVCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
NovoCure Reports Q1 2026 Results: Full Earnings Call Transcript - Sahm
NovoCure Ltd (NVCR) Shares Surge 9.3% -- What GF Score of 70 Tel - GuruFocus
NovoCure (NASDAQ:NVCR) Trading 6.8% HigherShould You Buy? - MarketBeat
NVCR Maintained by Evercore ISI Group -- Price Target Raised to $20 - GuruFocus
Evercore Maintains Novocure(NVCR.US) With Buy Rating, Raises Target Price to $20 - Moomoo
NovoCure Ltd (NVCR) Q1 2026 Earnings Call Highlights: Revenue Gr - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
NovoCure (NVCR) Earnings Story Centers On 20.6% Revenue Growth Versus Ongoing Losses - simplywall.st
MSN Money - MSN
NovoCure Earnings Call Highlights Growth, One-Time Hit - TipRanks
NovoCure Limited Q1 2026 Earnings Call Summary - Yahoo Finance
NovoCure (NASDAQ:NVCR) Announces Earnings Results - MarketBeat
NovoCure Ltd Q1 2026 Financial Results: Revenues, Losses, and Key Forward-Looking Statements - Minichart
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $48 - Moomoo
NovoCure (NVCR) Q1 2026 Earnings Transcript - The Globe and Mail
NovoCure Limited (NVCR) Reports Strong Q1 2026 Results and FDA A - GuruFocus
Novocure (NVCR) Shares Jump 22% on Strong Q1 Revenue and Raised Outlook - GuruFocus
NovoCure (NASDAQ:NVCR) Shares Gap UpShould You Buy? - MarketBeat
NovoCure: Q1 Earnings Snapshot - theheraldreview.com
NVCR Stock Update: Insights on Current Market Trends - GuruFocus
Novocure (NVCR) Reports Strong Q1 Revenue Growth - GuruFocus
Novocure Jumps On Q1 Revenue Growth; Lifts FY26 Revenue Guidance - RTTNews
NovoCure (NVCR) Q1: EPS -0.62 (miss vs -0.51 est.), Revenue $174 - GuruFocus
NovoCure Reports Revenue Growth Driven by New Pancreatic Cancer Therapy - HarianBasis.co
NovoCure Q1 Earnings Call Highlights - MarketBeat
NovoCure Limited 2026 Q1ResultsEarnings Call Presentation (NASDAQ:NVCR) 2026-04-30 - Seeking Alpha
NovoCure (NVCR) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
NovoCure Ltd reports first quarter 2026 earnings performance - Traders Union
Novocure reports Q1 2026 revenue $174.1M, adjusted EBITDA $(0.3)M, net loss $71.1M - TradingView
Novocure (NASDAQ: NVCR) grows Q1 revenue and raises 2026 outlook - Stock Titan
NovoCure (NASDAQ: NVCR) grows Q1 2026 revenue while investing in new cancer indications - Stock Titan
New pancreatic cancer launch helps Novocure reach $174M in Q1 revenue - Stock Titan
Novocure earnings in focus as new pancreatic therapy debuts By Investing.com - Investing.com Nigeria
Novocure earnings in focus as new pancreatic therapy debuts - Investing.com UK
NovoCure (NASDAQ: NVCR) director converts options into 21,500 shares - Stock Titan
Vanguard (NVCR) holds 6.34M shares, 5.57% stake disclosed in 13G - Stock Titan
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Earnings Preview: Novocure to Report Financial Results Pre-market on April 30 - Moomoo
CEO Frank Leonard's new NovoCure (NASDAQ: NVCR) contract outlines pay - Stock Titan
NovoCure (NVCR) to Release Quarterly Earnings on Thursday - MarketBeat
NovoCure Ltd (NVCR) Stock Up 6.5% and Still Undervalued -- GF Sc - GuruFocus
NovoCure : Financial Reports 2026 novocure corporate responsibility report - marketscreener.com
Total debt per share of NovoCure Ltd. – SWB:038 - TradingView
NovoCure Ltd stock (JE00B6T5S470): Is tumor treating fields therapy strong enough to unlock new upsi - AD HOC NEWS
[DEF 14A] NovoCure Ltd Definitive Proxy Statement - Stock Titan
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
Novocure Ltd (NVCR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Leupin Nicolas | Former Chief Medical Officer |
Mar 04 '26 |
Sale |
13.31 |
1,100 |
14,636 |
102,979 |
| Weinberg Uri | Chf Medical and Innovation Ofr |
Mar 04 '26 |
Sale |
13.31 |
6,412 |
85,314 |
267,190 |
| Brackmann Christoph | Chief Financial Officer |
Mar 04 '26 |
Sale |
13.31 |
6,412 |
85,314 |
182,842 |
| Leonard Frank X | Chief Executive Officer |
Mar 04 '26 |
Sale |
13.31 |
5,607 |
74,603 |
493,793 |
| Paravasthu Mukund | Chief Operating Officer |
Mar 05 '26 |
Sale |
13.77 |
43,246 |
595,670 |
72,832 |
| Paravasthu Mukund | Chief Operating Officer |
Mar 04 '26 |
Sale |
13.31 |
5,377 |
71,543 |
116,078 |
| Puri Michal Nath | Chief Human Resources Officer |
Mar 04 '26 |
Sale |
13.31 |
1,100 |
14,636 |
201,322 |
| DOYLE WILLIAM F | Executive Chairman |
Mar 03 '26 |
Sale |
12.98 |
71,887 |
932,883 |
328,397 |
0.41%
0.93%
大文字化:
|
ボリューム (24 時間):